Archexin, A Novel AKT-1 Specific Inhibitor for the Treatment of Metastatic Renal Cancer – Preliminary Stage 1 Data Jan 7, 2016
New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer Dec 8, 2015
RX-0201, An Anti-Sense Targeting AKT-1 to Treat Metastatic Renal Cancer – Preliminary Stage 1 Data Nov 6, 2015
A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors May 29, 2015
A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma May 29, 2015
A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors May 29, 2015
A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors May 29, 2015
Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902) Apr 18, 2015
![Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)](https://d1io3yog0oux5.cloudfront.net/_fb078356935db8f3e32d066bfceb70c4/rexahn/db/432/3058/pdf_thumbnail.jpg "Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)")
